Status:
TERMINATED
A Study Comparing the Safety and Efficacy of Ziprasidone and Risperidone for the Treatment of Chronic Schizophrenia
Lead Sponsor:
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Conditions:
Schizophrenia
Eligibility:
All Genders
18-70 years
Phase:
PHASE3
Brief Summary
The purpose of this study is to compare the safety of ziprasidone and risperidone for the treatment of chronic schizophrenia. The primary purpose is to differentiate the effects of ziprasidone and ris...
Eligibility Criteria
Inclusion
- Diagnosis of schizophrenia
- CGI-S score of 4 or less at baseline
Exclusion
- Concurrent antipsychotic treatment
- Treatment with antidepressants or mood stabilizers within 2 weeks of randomization
- Acute exacerbation of schizophrenia within 3 months of baseline
Key Trial Info
Start Date :
June 1 2003
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2003
Estimated Enrollment :
240 Patients enrolled
Trial Details
Trial ID
NCT00645515
Start Date
June 1 2003
End Date
December 1 2003
Last Update
February 21 2021
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
Bilbao, Vizcaya, Spain, 48010
2
Pfizer Investigational Site
Getxo, Vizcaya, Spain, 48990
3
Pfizer Investigational Site
Madrid, Spain, 28007